I think Abbott ($ABT) is a strong future play soon, and here is why

I work in the diabetes field and use/prescribe a LOT of glucose sensors: Libre (by Abbott $ABT) or Dexcom ($DXCM).

These are absolutely insanely helpful for diabetes population and even those without diabetes like to have them for exercise/training purposes.

I wore one for 2 weeks and it was so cool seeing what foods did to my sugars and it made me not want to eat high carb or bad foods.

These sensors also lower A1C without the need for medications (0.5%+) due to feedback from foods on diet. Abbott is also developing another wearable that measures ketones, alcohol, lactate I believe, which is pretty cool. Imagine if Abbott teams up with Garmin, Samsung, Apple, etc. ABT also pays a nice dividend.

Biggest risk is Apple is trying to develop a glucose sensor as well, but it could take years before it is FDA approved OR able to be synced with insulin pumps. I was going to wait for a pull back before buying ABT actually. Abott and DEXCOM are the only big two (Medtronic's Guardian sucks and no one uses Eversense) so there is a MOAT so to speak.

Abbott's libre was recently approved for use with pump technology, as only DEXCOM was able, so this will be huge also next year.

I am also kicking myself because when Ozempic came out 5+ years ago and we saw the weight loss effects at that time, I thought hm I should start a position in Novo Nordisk and Eli Lilly…yeah totally missed the run-up on that one sadly.